Comienzos
keyboard_arrow_right
keyboard_arrow_right
Adamas begins ADS-5102 Stage 2/3 clinical trial in Parkinsons disease Adamas Pharmaceuticals.
Rheumatology

Adamas begins ADS-5102 Stage 2/3 clinical trial in Parkinsons disease Adamas Pharmaceuticals.

‘Commencement of the Phase 2/3 scientific study of ADS-5102 culminates years of Adamas research into the usage of amantadine as a treatment for LID in Parkinson’s disease, and represents the well controlled first, powered research of amantadine targeted at licensure in this indication rigorously,’ said Gregory Went, Ph.D., Chief Executive Officer of Adamas.’ Dr. Matthew Stern, Professor of Neurology, University of Pennsylvania, an associate of Adamas’ Clinical Advisory Plank added, ‘LID represents a significant unmet want in advanced Parkinson’s disease.The study’s findings were reported at a meeting this past year of the American Heart Association. Research is underway to discover new treatments for cardiogenic shock. Dr. Hochman can be leading a trial to determine whether a substance known as nitric oxide synthase inhibitor might help shock sufferers by targeting excess nitric oxide production.

Abortion Pill Terminates Early Pregnancy Effectively A medical pregnancy termination at 4 to 9 weeks gestation could be achieve with administration of oral anti progesterone. The hormonal tablets shed uterine lining, and detach fetus from the same.